Long-term efficacy and safety of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 7 years in a real world setting: The experience of a reference Hospital in the Canary Islands

被引：0
作者：
Guimera-Martin-Neda, Francisco [1 ]
Garcia-Bustinduy, Marta [1 ]
Fagundo-Gonzalez, Eva [1 ]
Andres-Rosario, Ana [1 ]
Pestana-Eliche, Maria
机构：
[1] Hosp Univ Canarias, San Cristobal La Laguna, Spain
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
10567
引用
收藏
页码：AB233 / AB233
页数：1
相关论文
共 50 条
  • [1] Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
    Kimball, A. B.
    Papp, K. A.
    Wasfi, Y.
    Chan, D.
    Bissonnette, R.
    Sofen, H.
    Yeilding, N.
    Li, S.
    Szapary, P.
    Gordon, K. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (12) : 1535 - 1545
  • [2] Long-term efficacy of ustekinumab in moderate-to-severe psoriasis
    Kimball, A. B.
    Gordon, K. B.
    Fakharzadeh, S.
    Yeilding, N.
    Szapary, P. O.
    Schenkel, B.
    Guzzo, C.
    Li, S.
    Papp, K. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (04)
  • [3] Long-term outcomes of ustekinumab in patients with moderate-to-severe psoriasis in a university hospital
    Ossorio-Garcia, Lidia
    Collantes-Rodriguez, Cristina
    Jimenez-Gallo, David
    Linares-Barrios, Mario
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB179 - AB179
  • [4] Long-term efficacy of brodalumab in ustekinumab-responsive patients with moderate-to-severe psoriasis
    Green, Lawrence
    Hsu, Sylvia
    Papp, Kim A.
    Rastogi, Shipra
    Pillai, Radhakrishnan
    Israel, Robert J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB181 - AB181
  • [5] Long-Term Safety and Efficacy of Etanercept in Patients with Moderate-to-Severe Psoriasis: 5-Years Data Experience
    Conti, Andrea
    Galdo, Giovanna
    Greco, Maurizio
    Borsari, Stefania
    Lasagni, Claudia
    CLINICAL DRUG INVESTIGATION, 2013, 33 : S84 - S86
  • [6] Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
    Papp, K. A.
    Griffiths, C. E. M.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Hsu, M. -C.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (04) : 844 - 854
  • [7] A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
    Haque, Emily K.
    Azhar, Aaminah
    Corbett, John
    Frieder, Jillian
    Wang, Xuan
    Menter, Alan
    DERMATOLOGY AND THERAPY, 2020, 10 (05) : 1121 - 1135
  • [8] A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
    Emily K. Haque
    Aaminah Azhar
    John Corbett
    Jillian Frieder
    Xuan Wang
    Alan Menter
    Dermatology and Therapy, 2020, 10 : 1121 - 1135
  • [9] Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
    Kimball, A. B.
    Gordon, K. B.
    Fakharzadeh, S.
    Yeilding, N.
    Szapary, P. O.
    Schenkel, B.
    Guzzo, C.
    Li, S.
    Papp, K. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (04) : 861 - 872
  • [10] Long-term safety of ustekinumab in patients with moderate to severe psoriasis through up to 5 years of continuous follow-up
    Papp, Kim
    Reich, Kristian
    Lebwohl, Mark
    Szapary, Philippe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB205 - AB205
12345